IMVT vs INBX: fair value comparison
Immunovant, Inc. and Inhibrx Biosciences, Inc. · Updated 2026-10-19
IMVT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. INBX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IMVT currently ranks higher by quality score.
| IMVT | INBX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $26.73 | $89.83 |
| 12-month range | $18.74–$44.96 | $28.36–$141.84 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #243 of 301 Healthcare | #244 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | — | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: IMVT fair value analysis · INBX fair value analysis